


Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement – “Truth in Testimony”
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Susan C. Winckler, RPh, Esq.		
2. Your Title: Chief Executive Officer, Reagan-Udall Foundation for the Food and Drug Administration		
3. The Entity(ies) You are Representing: Reagan-Udall Foundation for the Food and Drug Administration		
4. Are you testifying on behalf of the Federal, or a State or local government entity? (If “Yes,” skip Item 5 and Item 6.)	Yes	No X
5. Grants, Contracts, and Payments a. Please list any <u>Federal grants or contracts</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2023</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed. The Foundation has been awarded in June 2026 a cooperative agreement by the FDA entitled “Pathways for Regulatory Innovation and Strategic Modernization (PRISM)”. While the work currently under this grant does not relate directly to the subject matter of the hearing, it is possible that additional projects relevant to this subject matter will emerge. b. Please list any <u>contracts or payments originating with a foreign government</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2023</u>. Only grants, contracts, or payments related to the subject matter of the hearing must be listed. NONE		
6. Are you a fiduciary (i.e., authorized to act on behalf of or for the benefit of) for any entity that has an interest in the subject matter of the hearing? Ms. Winckler is a Board Director and shareholder in Purgo Scientific--an early stage device company with a novel drug/device combo in preclinical work. The work of Purgo would likely not be affected by the reforms discussed during the hearing.	Yes X	No
7. Please attach your curriculum vitae to your completed disclosure form. ATTACHED		

Signature: 

Date: 7/13/26